We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Rheumatology

Journal Scan / Research · October 03, 2022

Lower Risk of Gout With SGLT2 Inhibitors vs DPP-4 Inhibitors in Type 2 Diabetes

Rheumatology (Oxford, England)

 

Additional Info

Rheumatology (Oxford, England)
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Rheumatology (Oxford) 2022 Sep 06;[EPub Ahead of Print], J Zhou, X Liu, OH Chou, L Li, S Lee, WT Wong, Q Zhang, C Chang, T Liu, G Tse, F Jing, BMY Cheung

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading